Overview
- President Donald Trump signed the order Saturday directing the FDA to use National Priority Vouchers to compress reviews for qualifying psychedelics to about 1–2 months, with Commissioner Marty Makary saying decisions could come as soon as this summer.
- The directive singles out ibogaine and instructs the FDA and DEA to create a Right to Try pathway so eligible patients with life‑threatening conditions can seek regulated access outside traditional trials.
- HHS and the VA are told to expand trials and share data, and at least $50 million will flow through ARPA‑H to support state programs researching psychedelics, with Texas already backing ibogaine studies.
- Following Monday’s rally in psychedelic stocks, Compass Pathways jumped about 37% and AtaiBeckley roughly 28%, while Enveric surged around 140%, as analysts said the order shows tangible federal support.
- Clinicians warn ibogaine can trigger dangerous heart rhythm problems and has been tied to dozens of deaths, so experts are urging strict cardiac screening and tightly controlled studies as access widens.